ImmuneOncia Therapeutics and Lonza signed an agreement for late-stage clinical manufacturing of Danburstotug (IMC-001), a fully human PD-L1 immune checkpoint antibody in development for relapsed/refractory NK/T-cell lymphoma. Lonza will support both drug substance and clinical drug product supply across its UK, Switzerland, and Basel/Stein sites. The collaboration aims to position the program for early regulatory momentum in a rare cancer indication while leveraging Lonza’s end-to-end development and manufacturing infrastructure. Danburstotug’s route through late-stage clinical supply highlights how contract manufacturers are increasingly central to oncology program timelines. For the broader biotech ecosystem, the deal signals ongoing demand for integrated biologics manufacturing capacity as companies push toward global clinical execution.